Marqeta Inc vs Smith & Nephew plc — how do they compare? Marqeta Inc trades at $15.62 (market cap $1.62B), while Smith & Nephew plc trades at $29.78 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 7.7× Marqeta Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | SNN | |
|---|---|---|
Market Cap | $1.62B | $12.54B |
Sector | Technology | Health |
52-Week High | $26.00 | $38.70 |
52-Week Low | $15.04 | $28.73 |
Enterprise Value | $935.36M | $15.57B |
Dividend Yield | — | 2.65% |
Signals from Pluang's Aura AI — not financial advice
MQ trades at $15.59, down slightly by 0.06%. The stock exhibits a bearish technical signal with strong selling pressure on moving averages. Fundamentally, the company shows improving revenue trends, with 2026 revenue projected at $677 million and a return to positive net income. Recent partnerships with Google and Riskified highlight strategic growth initiatives in digital payments and fraud prevention.
MQ's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but high valuation ratios and past earnings volatility present risks. Analyst consensus is a 'Hold' with a $19 price target, suggesting moderate upside potential from current levels amid competitive and execution challenges.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Trailing returns across standard periods
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →